Loading...
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Demetri, G Reichardt, P Kang, Y Blay, J Rutkowski, P Gelderblom, H Hohenberger, P Leahy, Michael G von Mehren, M Joensuu, H
Demetri, G
Reichardt, P
Kang, Y
Blay, J
Rutkowski, P
Gelderblom, H
Hohenberger, P
Leahy, Michael G
von Mehren, M
Joensuu, H
Citations
Altmetric:
Abstract
Until now, only imatinib and sunitinib have proven clinical benefit in patients with gastrointestinal stromal tumours (GIST), but almost all metastatic GIST eventually develop resistance to these agents, resulting in fatal disease progression. We aimed to assess efficacy and safety of regorafenib in patients with metastatic or unresectable GIST progressing after failure of at least imatinib and sunitinib.
Description
Date
2013-01-26
Publisher
Collections
Keywords
Type
Article
Citation
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. 2013, 381 (9863):295-302 Lancet